La agencia europea del medicamento (EMEA) aprueba Relistor™: El primer tratamiento para el estreñimiento inducido por opioides

• Autores: G. Markham, J. Espley
• Localización: Revista de la Sociedad Española del Dolor (SED), ISSN 1134-8046, Vol. 15, Nº. 6, 2008, págs. 417-419
• Idioma: español
• Títulos paralelos:
  • European medicines agency (EMEA) aproves relistor™: The first-in-class treatment of opioid-induced constipation (OIC) in advanced-illnes patients
• Enlaces
  • Texto completo (pdf)
• Referencias bibliográficas
  • Davies, E, Higginson, I. (2004). Better Palliative Care for Older People. WHO.
  • Gutstein, HB, Akil, H. (2006). Goodman & Gilman’s The Pharmacological Basis of Therapeutics. McGraw-Hill. New York^eNY NY.
  • Fallón, MT. (1999). Constipation in cáncer patients: prevalence, pathogenesis, and cost-related issues. Eur J Pain.. 3. 3-7
  • Emanuel, EJ, Emanuel, LL. (2005). Harrison’s Principies of Internal Medicine. 16. McGraw-Hill. New York^eNY NY.
  • Miniño, AM, Heron, M, Murphy, SL. Deaths: final data for 2004. Health E-Stats. Released November 24, 2006.
  • NHPCO’s Facts and Figures-2005 Findings.
  • Thomas, J, Karver, S, Cooney, GA. Methylnaltrexone for Opioid Induced Constipation in Advanced Illness. New England Journal of Medicine. 358....